Literature DB >> 2540246

Humoral immune response to cytomegalovirus Towne vaccine strain and to Toledo low-passage strain.

E Gönczöl1, J Ianacone, G Furlini, W Ho, S A Plotkin.   

Abstract

Neutralization and immunoblot or immunoprecipitation assays of serum samples from seronegative or seropositive volunteers immunized with the attenuated Towne and challenged with the virulent Toledo cytomegalovirus strains were carried out. Titers of neutralizing antibodies differed as a function of the strain used for immunization. All serum samples with neutralizing activity detected a 58-kDa protein that is the abundant component of the major glycoprotein complex of the envelope, suggesting that this protein complex is involved in the induction of neutralizing antibodies. Complement-independent neutralizing activity was found to develop later than complement-dependent activity, and no correlation was observed between complement-independent titers of neutralizing antibodies and antibody to the 86-kDa protein, which bears a complement-independent neutralizing epitope. Antibodies to the 66-kDa major tegument protein were present early after infection but were not correlated with serum neutralizing activity.

Mesh:

Substances:

Year:  1989        PMID: 2540246     DOI: 10.1093/infdis/159.5.851

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  7 in total

1.  Analysis of human antibody responses to human cytomegalovirus envelope glycoproteins found in two families of disulfide linked glycoprotein complexes designated gC-I and gC-II.

Authors:  B Kari; R Gehrz
Journal:  Arch Virol       Date:  1990       Impact factor: 2.574

2.  Rationally designed chemokine-based toxin targeting the viral G protein-coupled receptor US28 potently inhibits cytomegalovirus infection in vivo.

Authors:  Katja Spiess; Mads G Jeppesen; Mikkel Malmgaard-Clausen; Karen Krzywkowski; Kalpana Dulal; Tong Cheng; Gertrud M Hjortø; Olav Larsen; John S Burg; Michael A Jarvis; K Christopher Garcia; Hua Zhu; Thomas N Kledal; Mette M Rosenkilde
Journal:  Proc Natl Acad Sci U S A       Date:  2015-06-15       Impact factor: 11.205

Review 3.  Perinatal cytomegalovirus and varicella zoster virus infections: epidemiology, prevention, and treatment.

Authors:  Kristy M Bialas; Geeta K Swamy; Sallie R Permar
Journal:  Clin Perinatol       Date:  2014-11-28       Impact factor: 3.430

4.  Intranasal immunization with recombinant vesicular stomatitis virus expressing murine cytomegalovirus glycoprotein B induces humoral and cellular immunity.

Authors:  Steven R Wilson; Jean H Wilson; Linda Buonocore; Amy Palin; John K Rose; Jon D Reuter
Journal:  Comp Med       Date:  2008-04       Impact factor: 0.982

Review 5.  Neuropathogenesis of congenital cytomegalovirus infection: disease mechanisms and prospects for intervention.

Authors:  Maxim C-J Cheeran; James R Lokensgard; Mark R Schleiss
Journal:  Clin Microbiol Rev       Date:  2009-01       Impact factor: 26.132

6.  Humoral immune response against human cytomegalovirus (HCMV)-specific proteins after HCMV infection in lung transplantation as detected with recombinant and naturally occurring proteins.

Authors:  J van Zanten; M C Harmsen; M van der Giessen; W van der Bij; J Prop; L de Leij; T H The
Journal:  Clin Diagn Lab Immunol       Date:  1995-03

7.  Novel microneutralization assay for HCMV using automated data collection and analysis.

Authors:  Anna Maria Abai; Larry R Smith; Mary K Wloch
Journal:  J Immunol Methods       Date:  2007-02-23       Impact factor: 2.303

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.